Search

Your search keyword '"Kirschbaum, Mark"' showing total 460 results
Start Over Author "Kirschbaum, Mark"
460 results on '"Kirschbaum, Mark"'

3. A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Tuscano, Joseph M, Maverakis, Emanual, Groshen, Susan, Tsao-Wei, Denice, Luxardi, Guillaume, Merleev, Alexander A, Beaven, Anne, DiPersio, John F, Popplewell, Leslie, Chen, Robert, Kirschbaum, Mark, Schroeder, Mark A, and Newman, Edward M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Lymphoma, Cancer, Clinical Research, Hematology, Clinical Trials and Supportive Activities, Rare Diseases, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Drug Resistance, Neoplasm, Female, Follow-Up Studies, Humans, Ipilimumab, Lymphoma, B-Cell, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Rituximab, Salvage Therapy, Survival Rate, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeBased on the potential for ipilimumab (I) to augment T-cell activation, we hypothesize that ipilimumab would augment the efficacy of rituximab (R) in patients with relapsed/refractory (R/R) CD20+non-Hodgkin's lymphoma (NHL). This phase I study aimed to identify a recommended phase 2 dose, document toxicities, and preliminarily assess efficacy and potential predictive biomarkers.Patients and methodsThirty-three patients with R/R CD20+B-cell lymphoma received R at 375 mg/m2weekly for 4 weeks and I at 3 mg/kg on day 1 and every 3 weeks for four doses. Responding patients went on to maintenance with each agent given every 12 weeks. To facilitate correlative analysis, the expansion phase randomized patients to simultaneous R+I versus R with I delayed 2 weeks.ResultsToxicity was manageable; no dose-limiting toxicity was observed at the doses studied. When considering the entire cohort, efficacy was modest, with an objective response rate (ORR) of 24% and median progression-free survival (PFS) of 2.6 months. However, in follicular lymphoma patients, the ORR was 58% with a median PFS of 5.6 months. The randomized comparison of R with R+I demonstrated that R+I resulted in more effective B-cell depletion (BCD). Both B-cell depletion and the ratio of CD45RA-regulatory T cell (Treg) to Treg were associated with response at all time points.ConclusionsThe combination of R+I has manageable toxicity and encouraging efficacy in R/R follicular lymphoma. The ratio of CD45RA-Tregs to total Tregs, and peripheral BCD should be studied further as potential predictors of response.

Published
2019

4. A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study

Author

Kirschbaum, Mark H, Frankel, Paul, Synold, Timothy W, Xie, Zhiliang, Yen, Yun, Popplewell, Leslie, Chen, Robert, Aljitawi, Omar, Tuscano, Joseph M, Chan, Kenneth K, and Newman, Edward M

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Digestive Diseases, Clinical Research, Clinical Trials and Supportive Activities, Orphan Drug, Liver Disease, Hematology, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Drug Monitoring, Female, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Oligodeoxyribonucleotides, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Ribonucleotide Reductases, Treatment Outcome, Acute leukemia, GTI-2040, intermittent infusion, phase I trial, pharmacodynamics, pharmacokinetics, ribonucleotide reductase, Immunology, Cardiovascular medicine and haematology
Abstract

We performed a phase I study of GTI-2040, an antisense oligonucleotide against ribonucleotide reductase mRNA, on a novel dosing schedule of days 1-4 and 15-18 by continuous infusion to examine efficacy and tolerability in patients with leukemia. A dose of 11 mg/kg/d was safely reached. Dose-limiting toxicities (DLTs) at the higher levels included elevated troponin I and liver function enzymes. There were no objective responses to GTI-2040 in this study; 7/24 patients were able to complete the predetermined three infusion cycles. Pharmacokinetic and pharmacodynamic studies were performed, indicating a trend towards increasing intracellular drug levels and decreasing RRM2 gene expression with increasing doses. This dose schedule may be considered if appropriate combinations are identified in preclinical studies.

Published
2016

7. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

Author

Kirschbaum, Mark H, Foon, Kenneth A, Frankel, Paul, Ruel, Christopher, Pulone, Bernadette, Tuscano, Joseph M, and Newman, Edward M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Cancer, Rare Diseases, Pediatric Cancer, Pediatric, Clinical Research, Childhood Leukemia, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Adult, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents, Female, Histone Deacetylase Inhibitors, Humans, Hydroxamic Acids, Leukemia, Myeloid, Acute, Male, Middle Aged, Neoplasm Recurrence, Local, Sulfonamides, Treatment Outcome, Histone deacetylase inhibitor, leukemia, phase II, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

We performed a phase II study of belinostat in patients with acute myeloid leukemia (AML). In this open label phase II study (NCT00357032), patients with relapsed/refractory AML, or newly diagnosed patients with AML over the age of 60, were eligible. Belinostat was administered intravenously (IV) at a dose of 1000 mg/m(2) daily on days 1-5 of a 21-day cycle until progression or unacceptable toxicity. The primary endpoint was complete response (CR) rate, with secondary endpoints of overall response rate (CR + partial response [PR]), time to treatment failure (TTF), overall survival and safety. Twelve eligible patients with AML were enrolled, of whom six had received at least one prior line of therapy. No CR or PR was seen. Four patients had stable disease for at least five cycles. Grade 3 non-hematological toxicities occurred in four patients. Belinostat as monotherapy has minimal single-agent effect in AML on this dosing schedule.

Published
2014

8. Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Author

Jain, Nitin, Curran, Emily, Iyengar, Neil M, Diaz-Flores, Ernesto, Kunnavakkam, Rangesh, Popplewell, Leslie, Kirschbaum, Mark H, Karrison, Theodore, Erba, Harry P, Green, Margaret, Poire, Xavier, Koval, Greg, Shannon, Kevin, Reddy, Poluru L, Joseph, Loren, Atallah, Ehab L, Dy, Philip, Thomas, Sachdev P, Smith, Scott E, Doyle, L Austin, Stadler, Walter M, Larson, Richard A, Stock, Wendy, and Odenike, Olatoyosi

Subjects
Hematology, Cancer, Rare Diseases, Genetics, Childhood Leukemia, Clinical Research, Pediatric Cancer, Pediatric, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Benzimidazoles, Female, Genes, ras, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Mitogen-Activated Protein Kinase Kinases, Mutation, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-kit, Treatment Outcome, fms-Like Tyrosine Kinase 3, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe clinical relevance of targeting the RAS/RAF/MEK/ERK pathway, activated in 70% to 80% of patients with acute myelogenous leukemia (AML), is unknown.Experimental designSelumetinib is an oral small-molecule inhibitor of MAP-ERK kinase (MEK)-1/2. Forty-seven patients with relapsed/refractory AML or 60 years old or more with untreated AML were enrolled on a phase II study. Patients were stratified by FLT3 ITD mutation status. The primary endpoint was response rate (complete, partial, and minor). Leukemia cells were analyzed for extracellular signal-regulated kinase (ERK) and mTOR phosphorylation.ResultsCommon drug-related toxicities were grade 1-2 diarrhea, fatigue, nausea, vomiting, and skin rash. In the FLT3 wild-type cohort, six of 36 (17%) patients had a response [one partial response, three minor responses, two unconfirmed minor responses (uMR)]. No patient with FLT3 ITD responded. NRAS and KRAS mutations were detected in 7% and 2% of patients, respectively. The sole patient with KRAS mutation had uMR with hematologic improvement in platelets. Baseline p-ERK activation was observed in 85% of patients analyzed but did not correlate with a response. A single-nucleotide polymorphism (SNP) rs3733542 in exon 18 of the KIT gene was detected in significantly higher number of patients with response/stable disease compared with nonresponders (60% vs. 23%; P = 0.027).ConclusionsSelumetinib is associated with modest single-agent antileukemic activity in advanced AML. However, given its favorable toxicity profile, combination with drugs that target other signaling pathways in AML should be considered. The potential association of SNP rs3733542 in exon 18 of the KIT gene with antileukemic activity of selumetinib is intriguing, but will require validation in larger trials.

Published
2014

10. Supplementary Table 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Author

Jain, Nitin, primary, Curran, Emily, primary, Iyengar, Neil M., primary, Diaz-Flores, Ernesto, primary, Kunnavakkam, Rangesh, primary, Popplewell, Leslie, primary, Kirschbaum, Mark H., primary, Karrison, Theodore, primary, Erba, Harry P., primary, Green, Margaret, primary, Poire, Xavier, primary, Koval, Greg, primary, Shannon, Kevin, primary, Reddy, Poluru L., primary, Joseph, Loren, primary, Atallah, Ehab L., primary, Dy, Philip, primary, Thomas, Sachdev P., primary, Smith, Scott E., primary, Doyle, L. Austin, primary, Stadler, Walter M., primary, Larson, Richard A., primary, Stock, Wendy, primary, and Odenike, Olatoyosi, primary

Published
2023
Full Text
View/download PDF

11. Supplemenary Figure 2 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Tuscano, Joseph M., primary, Maverakis, Emanual, primary, Groshen, Susan, primary, Tsao-Wei, Denice, primary, Luxardi, Guillaume, primary, Merleev, Alexander A., primary, Beaven, Anne, primary, DiPersio, John F., primary, Popplewell, Leslie, primary, Chen, Robert, primary, Kirschbaum, Mark, primary, Schroeder, Mark A., primary, and Newman, Edward M., primary

Published
2023
Full Text
View/download PDF

12. Supplemenary Figure 4 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Tuscano, Joseph M., primary, Maverakis, Emanual, primary, Groshen, Susan, primary, Tsao-Wei, Denice, primary, Luxardi, Guillaume, primary, Merleev, Alexander A., primary, Beaven, Anne, primary, DiPersio, John F., primary, Popplewell, Leslie, primary, Chen, Robert, primary, Kirschbaum, Mark, primary, Schroeder, Mark A., primary, and Newman, Edward M., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 5 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Tuscano, Joseph M., primary, Maverakis, Emanual, primary, Groshen, Susan, primary, Tsao-Wei, Denice, primary, Luxardi, Guillaume, primary, Merleev, Alexander A., primary, Beaven, Anne, primary, DiPersio, John F., primary, Popplewell, Leslie, primary, Chen, Robert, primary, Kirschbaum, Mark, primary, Schroeder, Mark A., primary, and Newman, Edward M., primary

Published
2023
Full Text
View/download PDF

14. Supplemental Figures 1 and 2 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Author

Andreeff, Michael, primary, Kelly, Kevin R., primary, Yee, Karen, primary, Assouline, Sarit, primary, Strair, Roger, primary, Popplewell, Leslie, primary, Bowen, David, primary, Martinelli, Giovanni, primary, Drummond, Mark W., primary, Vyas, Paresh, primary, Kirschbaum, Mark, primary, Iyer, Swaminathan Padmanabhan, primary, Ruvolo, Vivian, primary, González, Graciela M. Nogueras, primary, Huang, Xuelin, primary, Chen, Gong, primary, Graves, Bradford, primary, Blotner, Steven, primary, Bridge, Peter, primary, Jukofsky, Lori, primary, Middleton, Steve, primary, Reckner, Monica, primary, Rueger, Ruediger, primary, Zhi, Jianguo, primary, Nichols, Gwen, primary, and Kojima, Kensuke, primary

Published
2023
Full Text
View/download PDF

15. Supplemental Methods from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Author

Andreeff, Michael, primary, Kelly, Kevin R., primary, Yee, Karen, primary, Assouline, Sarit, primary, Strair, Roger, primary, Popplewell, Leslie, primary, Bowen, David, primary, Martinelli, Giovanni, primary, Drummond, Mark W., primary, Vyas, Paresh, primary, Kirschbaum, Mark, primary, Iyer, Swaminathan Padmanabhan, primary, Ruvolo, Vivian, primary, González, Graciela M. Nogueras, primary, Huang, Xuelin, primary, Chen, Gong, primary, Graves, Bradford, primary, Blotner, Steven, primary, Bridge, Peter, primary, Jukofsky, Lori, primary, Middleton, Steve, primary, Reckner, Monica, primary, Rueger, Ruediger, primary, Zhi, Jianguo, primary, Nichols, Gwen, primary, and Kojima, Kensuke, primary

Published
2023
Full Text
View/download PDF

16. Supplemenary Figure 7 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Tuscano, Joseph M., primary, Maverakis, Emanual, primary, Groshen, Susan, primary, Tsao-Wei, Denice, primary, Luxardi, Guillaume, primary, Merleev, Alexander A., primary, Beaven, Anne, primary, DiPersio, John F., primary, Popplewell, Leslie, primary, Chen, Robert, primary, Kirschbaum, Mark, primary, Schroeder, Mark A., primary, and Newman, Edward M., primary

Published
2023
Full Text
View/download PDF

17. Supplemenary Figure 6 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Tuscano, Joseph M., primary, Maverakis, Emanual, primary, Groshen, Susan, primary, Tsao-Wei, Denice, primary, Luxardi, Guillaume, primary, Merleev, Alexander A., primary, Beaven, Anne, primary, DiPersio, John F., primary, Popplewell, Leslie, primary, Chen, Robert, primary, Kirschbaum, Mark, primary, Schroeder, Mark A., primary, and Newman, Edward M., primary

Published
2023
Full Text
View/download PDF

18. Supplemental Tables 1-8 from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Author

Andreeff, Michael, primary, Kelly, Kevin R., primary, Yee, Karen, primary, Assouline, Sarit, primary, Strair, Roger, primary, Popplewell, Leslie, primary, Bowen, David, primary, Martinelli, Giovanni, primary, Drummond, Mark W., primary, Vyas, Paresh, primary, Kirschbaum, Mark, primary, Iyer, Swaminathan Padmanabhan, primary, Ruvolo, Vivian, primary, González, Graciela M. Nogueras, primary, Huang, Xuelin, primary, Chen, Gong, primary, Graves, Bradford, primary, Blotner, Steven, primary, Bridge, Peter, primary, Jukofsky, Lori, primary, Middleton, Steve, primary, Reckner, Monica, primary, Rueger, Ruediger, primary, Zhi, Jianguo, primary, Nichols, Gwen, primary, and Kojima, Kensuke, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure Legends from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Tuscano, Joseph M., primary, Maverakis, Emanual, primary, Groshen, Susan, primary, Tsao-Wei, Denice, primary, Luxardi, Guillaume, primary, Merleev, Alexander A., primary, Beaven, Anne, primary, DiPersio, John F., primary, Popplewell, Leslie, primary, Chen, Robert, primary, Kirschbaum, Mark, primary, Schroeder, Mark A., primary, and Newman, Edward M., primary

Published
2023
Full Text
View/download PDF

20. Table from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Tuscano, Joseph M., primary, Maverakis, Emanual, primary, Groshen, Susan, primary, Tsao-Wei, Denice, primary, Luxardi, Guillaume, primary, Merleev, Alexander A., primary, Beaven, Anne, primary, DiPersio, John F., primary, Popplewell, Leslie, primary, Chen, Robert, primary, Kirschbaum, Mark, primary, Schroeder, Mark A., primary, and Newman, Edward M., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 1 from Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Author

Jain, Nitin, primary, Curran, Emily, primary, Iyengar, Neil M., primary, Diaz-Flores, Ernesto, primary, Kunnavakkam, Rangesh, primary, Popplewell, Leslie, primary, Kirschbaum, Mark H., primary, Karrison, Theodore, primary, Erba, Harry P., primary, Green, Margaret, primary, Poire, Xavier, primary, Koval, Greg, primary, Shannon, Kevin, primary, Reddy, Poluru L., primary, Joseph, Loren, primary, Atallah, Ehab L., primary, Dy, Philip, primary, Thomas, Sachdev P., primary, Smith, Scott E., primary, Doyle, L. Austin, primary, Stadler, Walter M., primary, Larson, Richard A., primary, Stock, Wendy, primary, and Odenike, Olatoyosi, primary

Published
2023
Full Text
View/download PDF

22. Data from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Tuscano, Joseph M., primary, Maverakis, Emanual, primary, Groshen, Susan, primary, Tsao-Wei, Denice, primary, Luxardi, Guillaume, primary, Merleev, Alexander A., primary, Beaven, Anne, primary, DiPersio, John F., primary, Popplewell, Leslie, primary, Chen, Robert, primary, Kirschbaum, Mark, primary, Schroeder, Mark A., primary, and Newman, Edward M., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 1 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Tuscano, Joseph M., primary, Maverakis, Emanual, primary, Groshen, Susan, primary, Tsao-Wei, Denice, primary, Luxardi, Guillaume, primary, Merleev, Alexander A., primary, Beaven, Anne, primary, DiPersio, John F., primary, Popplewell, Leslie, primary, Chen, Robert, primary, Kirschbaum, Mark, primary, Schroeder, Mark A., primary, and Newman, Edward M., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 3 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Tuscano, Joseph M., primary, Maverakis, Emanual, primary, Groshen, Susan, primary, Tsao-Wei, Denice, primary, Luxardi, Guillaume, primary, Merleev, Alexander A., primary, Beaven, Anne, primary, DiPersio, John F., primary, Popplewell, Leslie, primary, Chen, Robert, primary, Kirschbaum, Mark, primary, Schroeder, Mark A., primary, and Newman, Edward M., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Methods from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Tuscano, Joseph M., primary, Maverakis, Emanual, primary, Groshen, Susan, primary, Tsao-Wei, Denice, primary, Luxardi, Guillaume, primary, Merleev, Alexander A., primary, Beaven, Anne, primary, DiPersio, John F., primary, Popplewell, Leslie, primary, Chen, Robert, primary, Kirschbaum, Mark, primary, Schroeder, Mark A., primary, and Newman, Edward M., primary

Published
2023
Full Text
View/download PDF

26. Data from Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

Author

Andreeff, Michael, primary, Kelly, Kevin R., primary, Yee, Karen, primary, Assouline, Sarit, primary, Strair, Roger, primary, Popplewell, Leslie, primary, Bowen, David, primary, Martinelli, Giovanni, primary, Drummond, Mark W., primary, Vyas, Paresh, primary, Kirschbaum, Mark, primary, Iyer, Swaminathan Padmanabhan, primary, Ruvolo, Vivian, primary, González, Graciela M. Nogueras, primary, Huang, Xuelin, primary, Chen, Gong, primary, Graves, Bradford, primary, Blotner, Steven, primary, Bridge, Peter, primary, Jukofsky, Lori, primary, Middleton, Steve, primary, Reckner, Monica, primary, Rueger, Ruediger, primary, Zhi, Jianguo, primary, Nichols, Gwen, primary, and Kojima, Kensuke, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure Legends for Table 1 and Figures 1-6 from Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels

Author

Kretzner, Leo, primary, Scuto, Anna, primary, Dino, Pamela M., primary, Kowolik, Claudia M., primary, Wu, Jun, primary, Ventura, Patrick, primary, Jove, Richard, primary, Forman, Stephen J., primary, Yen, Yun, primary, and Kirschbaum, Mark H., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figures 1-6 from Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels

Author

Kretzner, Leo, primary, Scuto, Anna, primary, Dino, Pamela M., primary, Kowolik, Claudia M., primary, Wu, Jun, primary, Ventura, Patrick, primary, Jove, Richard, primary, Forman, Stephen J., primary, Yen, Yun, primary, and Kirschbaum, Mark H., primary

Published
2023
Full Text
View/download PDF

41. Sustaining rural pharmacy workforce understanding key attributes for enhanced retention and recruitment.

Author

Terry, Daniel, Peck, Blake, Hills, Danny, Bishop, Jaclyn, Kirschbaum, Mark, Obamiro, Kehinde, Phan, Hoang, Baker, Ed, and Schmitz, David

Subjects
PILOT projects, USER-centered system design, OCCUPATIONAL achievement, RESEARCH evaluation, CONFIDENCE intervals, RESEARCH methodology evaluation, RURAL conditions, RESEARCH methodology, CROSS-sectional method, DRUGSTORES, EMPLOYEE recruitment, INTERVIEWING, EXECUTIVES, QUANTITATIVE research, COMMUNITIES, POPULATION geography, FAMILIES, LABOR supply, PHARMACISTS, SURVEYS, CRONBACH'S alpha, INTER-observer reliability, HOSPITAL pharmacies, QUESTIONNAIRES, PSYCHOSOCIAL factors, PROFESSIONAL autonomy, WAGES, DESCRIPTIVE statistics, INTRACLASS correlation, RESEARCH funding, SOCIODEMOGRAPHIC factors, DATA analysis software, MEDICAL practice, EMPLOYEE retention, ALGORITHMS
Abstract

Objective: To pilot the Pharmacist Community Apgar Questionnaire (PharmCAQ) and evaluate its usability and capacity to develop a greater understanding of the unique factors that impact the rural recruitment and retention of pharmacists. Design: Cross‐sectional design involving face‐to‐face, telephone or video conferencing interviews. Setting: Twelve rural communities across Tasmania and Western Victoria, Australia. Participants: Participants (n = 24) included pharmacists, a Director of Clinical Services, pharmacy practice managers and senior pharmacy assistants. Main Outcome Measures: Interviews enabled the completion of the PharmCAQ, which assigns quantitative values to 50 key factors to ascertain a community's strengths and challenges associated with recruitment and retention and their relative importance to the pharmacist workforce. Results: The cumulative PharmCAQ scores indicated the tool was sensitive enough to differentiate high‐ and low‐performing communities. Overall, the highest‐rated factors considered most vital to pharmacist recruitment and retention were the reputation of the pharmacy, the ability of the pharmacist to be independent and autonomous, the loyalty of the community to the pharmacy, the level and stability of monetary compensation and the breadth of tasks available to a pharmacist. Conclusions: This study identified the strengths and challenges of participating communities and provided an insight into the shared factors to consider in recruiting and retaining pharmacists. Further, each community has unique strengths that can further be promoted in recruitment, flagging where limited resources are best used to address site specific challenges. This is more likely to ensure the matching of the right candidate with the right community. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

44. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

Author

Piekarz, Richard L., Frye, Robin, Prince, H. Miles, Kirschbaum, Mark H., Zain, Jasmine, Allen, Steven L., Jaffe, Elaine S., Ling, Alexander, Turner, Maria, Peer, Cody J., Figg, William D., Steinberg, Seth M., Smith, Sonali, Joske, David, Lewis, Ian, Hutchins, Laura, Craig, Michael, Fojo, A. Tito, Wright, John J., and Bates, Susan E.

Published
2011
Full Text
View/download PDF

47. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data

Author

Bates, Susan E., Eisch, Robin, Ling, Alexander, Rosing, Douglas, Turner, Maria, Pittaluga, Stefania, Prince, Miles H., Kirschbaum, Mark H., Allen, Steven L., Zain, Jasmine, Geskin, Larisa J., Joske, David, Popplewell, Leslie, Cowen, Edward W., Jaffe, Elaine S., Nichols, Jean, Kennedy, Sally, Steinberg, Seth M., Liewehr, David J., Showe, Louise C., Steakley, Caryn, Wright, John, Fojo, Tito, Litman, Thomas, and Piekarz, Richard L.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results